Compare Gilead Sciences, Inc. (GILD) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Palo Alto Networks Inc — how do they compare? Gilead Sciences, Inc. trades at $136.14 (market cap $168.35B), while Palo Alto Networks Inc trades at $379 (market cap $312.80B). The key difference: Palo Alto Networks Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| GILD | PANW | |
|---|---|---|
Market Cap | $168.35B | $312.80B |
Sector | Health | Technology |
52-Week High | $155.80 | $385.04 |
52-Week Low | $110.56 | $141.67 |
Enterprise Value | $191.42B | $311.76B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Palo Alto Networks (PANW) trades at $384.29, down 0.19% on the day, with a bullish technical signal supported by moving averages and strong institutional sentiment. Revenue grew to $9.22B in FY2025, with net income of $1.13B, though valuation ratios like P/E of 333.74 and P/S of 26.64 appear elevated. Recent news highlights AI-driven cybersecurity demand and a China regulatory review, while the company beat EPS estimates in three consecutive quarters.
Outlook remains positive due to robust AI security growth and analyst consensus, but risks include high valuation, integration costs from acquisitions, and geopolitical scrutiny. The stock's proximity to its 52-week high suggests cautious optimism, with upside potential tied to execution on AI initiatives and cybersecurity spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
